Raman spectroscopy was employed for the characterisation of blood plasma samples from patients at different stages of breast cancer. Blood plasma samples taken from clinically diagnosed breast cancer patients were compared with healthy controls using multivariate data analysis techniques (principal components analysis -PCA) to establishRaman spectral features which can be considered spectral markers of breast cancer development.All the stages of the disease can be differentiated from normal samples. It is also found that stage 2 and 3 are biochemically similar, but can be differentiated from each other by PCA. The Raman spectral data of the stage 4 is found to be biochemically distinct, but very variable between patients.Raman spectral features associated with DNA and proteins were identified, which are exclusive to patient plasma samples. Moreover, there are several other spectral features which are strikingly different in the blood plasma samples of different stages of breast cancer. In order to further explore the potential of Raman spectroscopy as the basis of a minimally invasive screening technique for breast cancer diagnosis and staging, PCA-Factorial Discriminant Analysis (FDA) was employed to classify the Raman spectral datasetsof the blood plasma samples of the breast cancer patients, according to different stages of the disease, yielding promisingly high values of sensitivity and specificity for all stages.
Introduction
Breast cancer is a major threat to the health of women, primarily, all over the world. According to the International Agency for Research on Cancer(IARC), of all diagnosed cancers, about 11.9%
(1.7 million cases)are of the breast [1] . Its incidence is spreading globally, except in the United
States, where it is comparatively stable [2] , and, in 2017, and estimated 250,000 diagnosed cases of female breast cancer and 40,000 associated deaths were reported [3] .According to the U.S.
National Cancer Institute, the associated cost of the care of breast cancer will reach approximately $20.5 billion in 2020 [4] . However, the survival is more favorable, although the mortality rateis lower in developed countries than developing regions [5] . The contribution of genetic factors in breast cancer is reported to be only 5-10% [6] [7] , posing a challenge for potential prevention. The variable risk factors may include late childbearing, lactation failure, weight gain after menopause, nulliparity, lack of exercise, and alcohol consumption [8] . Breast cancer cells develop in the tissue of the mammary gland and have an evolution period of 7 years, as 100-300 days are required to double the number of cancer cells and the emergence of breast neoplasm requires 30 doublings [9] .
This highlights the potential importance of early detection and the developments of screening techniques which are capable of detecting the early stage abnormalities at a micro level. The different stages of cancer are an important element ofthediagnosis protocol, particularly for the survival prospects. The classification depends on the size of tumour (T), involvement of lymph nodes (N) and metastasis/no metastasis to other organs (M) [5] . In stage 0, caner has not developed further than the instigation point, while in stage 1, it has spread to some fatty breast tissues, it has become a bit bigger in size at stage 2 and has spread up to 3 lymph nodes, while in stage 3, it has spread to the chest wall. Critically at stage 4, also referred to as the metastatic phase, it has spread from the breast or lymph nodes to bones, liver, lungs and brains, beyond which there is no further stage classification.
In the field of medicine/ clinical practice, the range of techniques which are currently used for the diagnosis and subsequent treatment of breast cancer include fluorescence, optical bioluminescence, optical imaging, MRI (magnetic resonance imaging), X-ray imaging and ultrasound [10] [11] [12] . These techniques have low sensitivity and resolution, and X-ray employs potentially harmful radiation which can be very risky for patients. Moreover, when visible on xray or MRI, the cancer is already at an advanced stage. There is a clinical need for a high sensitivity, real time, label free and less invasive method to screen patients for early stage symptoms, and also to establish the stage of development of the disease.
Raman spectroscopy has been demonstrated to provide specific molecular signatures of a variety of biological samples and other materials [13] [14] [15] . It can detect changes of molecular composition and structure which take place during the formation of a tumour, in the constituents of cells and tissue such as nucleic acids, carbohydrates, proteins and lipids. Blood carries the metabolic products of a tumour which can be monitored during circulation. As these biochemical changes are manifest prior to the appearance of clinical symptoms commonly detected by medical imaging, Raman spectroscopy has the potential to provide early diagnosis of the cancer [16] [17] [18] [19] [20] [21] [22] .
Regarding number of studies have already explored Raman spectroscopy for the diagnosis of breast cancer based on blood plasma/serum samples from clinically diagnosed patients. Bilal et al.
applied Partial least squares(PLS) regression analysis to the Raman spectral data acquired from blood serum of breast cancer and healthy individuals and coefficients of regression were determined which are associated with the changes at the bio-molecular level, hence indicating the development of the disease [23] . In another study, Pichardo-Molina et al. applied Raman spectroscopy along with principal components analysis (PCA) and PCA-Linear Discriminate Analysis (LDA) to breast cancer and control blood samples, identifying specific bands which distinguish breast cancer blood serum samples from the healthy ones [24] . To date, however, to the best of our knowledge, there have been no reports in which the technique has been applied to differentiate the different stages of breast cancer by using blood plasma samples.
In this study, Raman micro spectroscopy, supported by multivariate analyses, is employed to analyse the characteristic signatures of blood plasma samples from patients diagnosed with breast cancer of either stage 2, 3 or 4, and to differentiate them from both normal healthy controls and from each other. In doing so, the underlying biochemical origin of the differentiating features is explored, and the potentialof the technique for minimally invasive diagnosis and staging of the disease is demonstrated. The assignments of the Raman spectralfeatures used in interpretation of the results were taken from theliterature [25] [26] [27] [28] [29] and are described in Table 1 .
Materials and methods

Sample preparation and protocol
Data preprocessing
All data processing of the Raman spectra was performed using Matlab 7.2 and established protocols [30] . Data pre-processing included smoothing, baseline correction, vector normalisation and substrate removal. All spectra, including substrate backgrounds, were vector normalised and smoothed using a Savitzky-Golay smoothing method (order 5,13 point window). A rubber band correction for baseline removal for all the spectra was carried out and the substrate spectra were subtracted from each spectrum.
Data analysis
Principal components analysis ( 
Peak assignments References
625
Nucleotide conformation [32] 689 Nucleotide conformation [33] 700 n (C-S) trans (aminoacid methionine) [34] 714-6 C-N (membrane phospholipids head)/adenine CN2(CH3)3 (lipids) [35] Tryptophan, d (ring) [34] 770 Phosphate [36] 778 Phosphatidylinositol [37] 788 phosphodiester bands in DNA [38] 798 CH out of plane deformation [39] 828 tyrosine/protein [40] 848 Most probably due to single bond stretching vibrations for the amino acids and valine.
Tyrosine (Fermi resonance of ring fundamental and overtone) [41] [34] 857 (collagen type I) [40] 885 Disaccharide (cellobiose), (C-O-C) skeletal mode [34] 911 Glucose [37] 917 Proline, hydroxyproline [40] 1100 C-C vibration mode of the gauche-bonded chain [42] 1138 n(C-C)-lipids, fatty acids [34] 1145 n(C-C)-lipids, fatty acids [34] 1173 Cytosine, guanine [43] 1185 Anti-symmetric phosphate vibrations [44] 1268 d (=C-H) (phospholipids) [45] 1285 Typical phospholipids [46] 1307 CH3/CH2twisting, wagging &/or bending mode of collagens & lipids [40] 1319 Guanine (B,Z-marker) [43] ns COO2 (IgG) [45] 1440 CH2 deformation in normal breast tissue [47] 1609 Cytosine (NH2) [43] 1660-63 DNA [48] Results and discussion After thediagnosis of breast cancer, it is important to determine the staging of the cancer, because this will help to know that how far the disease has progressed and also to determine the best way to contain and eliminate the breast cancer.Stage 2 breast cancer is still in the earlier stages, but there is evidence that the cancer has begun to grow or spread. It is still contained to the breast area and is generally very effectively treated. On the other hand, stage 3 is known to be an advanced stage of breast cancer, at which the cancer has started to invade the surrounding tissues of the breast. In this regard, Raman spectroscopy can potentially be of benefit in the differentiation of these stages of breast cancer, hence leading to early diagnosis which could be useful for the This study advances previously published work related to the use of Raman spectroscopy for the characterization/diagnosis of breast cancer by using blood plasma/serum samples from clinically diagnosed patients, as the spectral markers of689 (Nucleotide conformation), 788 (phosphodiester bands in DNA), 828 (tyrosine/protein), 848 (most probably due to single bond stretching vibrations for amino acids and polysaccharides) and 1663 cm -1 (DNA) have not previously been identified.
In these reports, Bilal et al. applied Partial least squares(PLS) regression analysis to the Raman spectral data acquired from blood serum of breast cancer and healthy individuals and coefficients of regression were determinedwith sensitivity of 90% and specificity 75% which are associated with the changes at the bio-molecular level [23] , while in the current study sensitivity and specificity have been found to be as high as 100% in the comparison of control and breast cancer samples. In another study, Pichardo-Molina et al. applied Raman spectroscopy along with principal components analysis (PCA) and PCA-Linear Discriminate Analysis (LDA) to breast cancer and control blood samples, identifying specific bands which distinguish breast cancer blood serum samples from the healthy ones [24] . In the current study, the technique has been applied to differentiate the different stages of breast cancer by using blood plasma samples and such Raman spectral changes are observed in the stage wise comparison for the breast cancer which indicates the biochemical changes taking place during the development and progression of breast cancer through different stages. In order to quantify the diagnostic potential of the spectroscopic technique, a further classification of the control and breast cancer using PCA-FDA was carried out. The results are shown in Table   2 , which indicates that the presence of breast cancer in patients can be detected in plasmawith a sensitivity of 100% and a specificity of 100%. 
